A systematic review of the role of vitamin insufficiencies and supplementation in COPD by Tsiligianni, Ioanna G & van der Molen, Thys
REVIEW Open Access
A systematic review of the role of vitamin
insufficiencies and supplementation in COPD
Ioanna G Tsiligianni
*, Thys van der Molen
Abstract
Background: Pulmonary inflammation, oxidants-antioxidants imbalance, as well as innate and adaptive immunity
have been proposed as playing a key role in the development of COPD. The role of vitamins, as assessed either by
food frequency questionnaires or measured in serum levels, have been reported to improve pulmonary function,
reduce exacerbations and improve symptoms. Vitamin supplements have therefore been proposed to be a
potentially useful additive to COPD therapy.
Methods: A systematic literature review was performed on the association of vitamins and COPD. The role of
vitamin supplements in COPD was then evaluated.
Conclusions: The results of this review showed that various vitamins (vitamin C, D, E, A, beta and alpha carotene)
are associated with improvement in features of COPD such as symptoms, exacerbations and pulmonary function.
High vitamin intake would probably reduce the annual decline of FEV1. There were no studies that showed benefit
from vitamin supplementation in improved symptoms, decreased hospitalization or pulmonary function.
Introduction
COPD in all stages of severity is a very prevalent disease
and a great burden for patients and society [1]. In afflu-
ent countries COPD is related to smoking over a long
period of time, whereas in many other countries it is
also related to indoor and outdoor air pollution [1]. The
pathology of chronic obstructive pulmonary disease
include pulmonary inflammation, oxidants-antioxidants
imbalance, protease-antiprotease imbalance, and both
innate and adaptive immunity [2,3]. Smoking cessation
has been proven to be effective in stopping further dete-
rioration of pulmonary function, reducing symptoms
and improving overall health [4]. Smoking cessation
however, seems to have only limited influence on the
inflammatory process that is associated with COPD.
This inflammatory process is probably initiated by oxi-
dative stress and forms the basis of the pathophysiology
of COPD [5-8]. Thus the inflammatory process that is
associated with COPD seems to be triggered by noxious
gasses such as smoking and serious indoor or outdoor
air pollution. Oxidative stress caused by these noxious
gasses at the level of the epithelium of the bronchial
tree might have play a key role in this inflammatory
process. It is therefore possible that anti oxidant therapy
or an intensive anti oxidant diet could have an influence
on the inflammatory process and the progression of
COPD. Over the last two decades a number of studies
have suggested that COPD risk is associated with vita-
mins that all have antioxidant properties and with an
anti oxidant diet. Low diet-intake of vitamins has been
reported to reduce natural defenses and increase the
possibility of airway inflammation [9]. Furthermore, a
higher intake of fruits and vegetables was associated
with a lower risk of COPD, lower mortality and an
improvement of spirometric values [10-17].
When levels of vitamins were measured in the serum
they were found to be significantly lower in COPD
patients than in control subjects [18]. The association of
vitamins with pulmonary diseases is further supported by
a meta-analysis of 40 studies in patients with asthma. This
meta-analysis revealed that relatively low dietary intake of
vitamins A and C were associated with statistically signifi-
cant increased odds of asthma and wheezing [19].
Al a r g en u m b e ro fs t u d i e sa nd reviews highlight an
association of vitamins with lung function in healthy
subjects and COPD patients [20-27]. Recently a rando-
m i z e dc o n t r o l l e dt r i a ls u g g e s t e dt h a tad i e t a r ys h i f tt o
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improvement in lung function [25]. Furthermore, several
studies associate vitamins with a reduction in symptoms,
respiratory infections and exacerbations [28-37].
Although for vitamin D the role in respiratory diseases
has been clarified through its implication in immunity,
for most other vitamins the mechanism of action is less
clear [38-42]. Indeed we know that 1,25-dihydroxyvita-
min D stimulates both innate and adaptive immunity, in
addition to mineralization and calcium homeostasis.
Further support on the important role of Vitamin D is
given by the fact that it regulates genes that are impli-
cated in apoptosis and cellular proliferation [39], known
to be an important step in COPD pathogenesis [42].
Vitamin D has both immunomodulatory and antiiflam-
matory properties [43]. For vitamin A, B, C, and E, stu-
dies highlight their role in COPD risk as well as their
connection with COPD outcomes such as symptoms
and improvement in spirometric values, without a clear
mechanism of action. This article aims to update the
knowledge we have about the association between vita-
min intake and COPD in outcome measures, as well as
to assess the potential role of vitamin supplements.
Methods
A systematic literature search was performed from 1989
until June 2010 in Pubmed, Embase and Cochrane Col-
laboration containing the following keywords: COPD in
conjunction with smoking, gene polymorphisms, vita-
mins, FEV1, vitamin C, vitamin E, vitamin D, vitamin A,
b-carotene, and vitamin supplements. Further articles
were identified from the reference lists of the included
articles. In order to be as accurate as possible we
included in the present review only studies that have
measured serum vitamin levels or used validated food
frequency questionnaires to assess the role of vitamins.
Other dietary factors -cured meats, fish, whole grains
and alcohol- that have been reported to be associated
with the risk of chronic obstructive pulmonary disease or
with an increase in symptoms were not included in this
review [44-51]. Further we did not examine the influence
of caloric intake on COPD. Weight loss and muscle wast-
ing, considered complications of COPD strongly asso-
ciated with diet, are also not included in the review.
Results
Methods of assessing vitamin status: which is best?
The literature reports two essentially different ways to
measure vitamins: Serum levels and Food Frequency
Questionnaires (FFQ). Both measures have their advan-
tages and disadvantages.
Serum levels of vitamins
The assessment of serum levels of vitamins can have the
advantage of being more objective than patient’s
reported intake. However, serum level assessment of
vitamins has the disadvantage that they represent the
more recent intake, and for some vitamins such as vita-
min C, the levels in peripheral blood are not representa-
tive of intake and do not change accordingly [19,52].
Food Frequency questionnaire
Food frequency questionnaires on the other hand pre-
sent a large heterogeneity with differences in assessing
periods (from 1 day to two years), number of items on
food questionnaires (ranging from 44 to 350) and use of
portion size questions [53]. Further, it has been sug-
gested that FFQs do not always detect weak associations
[54]. Regarding vitamin C intake large differences were
found between FFQs that used portion size questions
instead of using standard portions [53]. Another pro-
blem regarding FFQ use is that it is difficult to deter-
mine which particular vitamin is associated with COPD
and if it is the vitamins in fruits and vegetables that are
associated with COPD, or another confounding nutrient.
Resveratrol for example, a phenolic antioxidant is pre-
sent in many fruits and is associated with anti-inflam-
matory activity [55,56]. Therefore it is not clear if in
some cases, the vitamins have the beneficial effect, or
other nutrients such as resveratrol with antioxidant and
anti-inflammatory properties.
Another important obstacle in FFQ is that an assess-
ment of vitamin D from food intake would lead to an
incorrect estimation in for example Mediterranean
countries where there is a high skin synthesis because of
the sunlight.
We found 14 references [31,57-69] that assessed the
relationship between a vitamin rich diet as assessed by a
FFQ and the subsequent improvement of spirometric
values and symptoms. Twelve studies [32,33,35,
52,63,70-76] measured serum levels of vitamins. For the
above mentioned reasons, and in order to have a more
precise overview, we decided to include both FFQ and
serum level studies.
Food intake patterns: Effect of vitamins on the risk of
developing COPD and associated mortality
Varraso et al in a study of 72,043 women identified 754
cases of newly diagnosed COPD [44]. In this study a
healthy diet (fruit, vegetables, fish, whole-grain products)
was compared with a Western diet (refined grains, cured
and red meats, desserts, French fries). The healthy diet
was associated with a lower risk of COPD [44]. This could
be considered to be due to the overall diet, or indicate a
possible positive effect of vitamins on COPD risk, as fruits
are considered sources rich with vitamins. From the same
author another study comparing the same patterns of diet
showed the same results in 111 self-reported cases of
newly diagnosed COPD in men [46]. Celik et al used a
food frequency questionnaire and found that the
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lower in COPD patients compared to the control group
[77]. Fruit intake was related to a lower 25-year incidence
of chronic bronchitis and emphysema [57] as well as spiro-
metry improvement [78]. A recent randomized controlled
trial has shown that a dietary shift to more anti-oxidant
f o o d ss u c ha sf r u i t sa n dv e g e t a b l e si sa s s o c i a t e dw i t h
improvement in lung function [25].
These studies showed a protective role of vitamins
against COPD but did not measure vitamins in serum
or with a FFQ. Therefore conclusions about the special
role of any vitamin in COPD could not be obtained.
Vitamin D and COPD
Vitamin D is extremely important for the human body. It
has a significant role in bone mineralization, in calcium
and phosphorous absorption, and is important in the
immune system [39,40]. It’s most important role however
is in bone structure development and bone turn over, as a
low vitamin D level is directly associated with osteoporosis.
The main sources of vitamin D are skin synthesis and diet.
The precursor form is 7-dehydrocholesterol which with
UVB is transformed to vitamin D3. Vitamin D3 is trans-
ported via the D-binding protein (DBP) to the liver where
with hydroxylation reactions transforms to 25(OH)D3 and
which is transported again by DBP to the kidneys where it
takes its active form of 1,25(OH)2D3. 25OHD3 can also be
transformed in 1,25(OH)2D3 in the immune cells [42].
Some studies showed a DBP Gc-1F allele presence that
was higher in COPD patients [79,80] and Schellenberg
et al found that the Gc2 homozygous genotype was protec-
tive for COPD [81]. Other polymorphisms associated with
vitamin D binding protein gene are related to clinical dif-
ferences in families with alpha-1-antitrypsin deficiency [82].
COPD is characterized by inflammation induced by
macrophages and neutrophils (innate immunity). COPD is
considered a disease where proinflammattory cytokines are
increased and has a Th2 response with a predominance of
CD8 lymphocytes (adaptive immunity). 1,25-dihydroxyvita-
min D stimulates innate immunity probably due to activa-
tion of cathelicidin (antimicrobial peptides) to enhance the
bacterial killing via Toll-like receptors [83,84]. Vitamin D
receptors (VDR) are present in various cells of both innate
(ie.macrophages) and adaptive immunity (i.e.T and B cells).
Vitamin D is able to modulate both types of immunity
therefore minimizing inflammation [85]. Vitamin D in gen-
eral is involved in modulating cellular proliferation, sup-
pressing TH cells, [86], downregulating cytokines such as
IL-2 [87], as well as in the inhibition of dendritic cells [88],
all of which are known to be important in the COPD path-
way. Regarding respiratory function, vitamin D plays a sig-
nificant role in airway remodeling through the inhibition of
TNFa and enhancement of Il-10 in immune cells [39]. Vita-
min D also seems to play a role as an alternative treatment
strategy to reverse glucocorticoid resistance through its
ability to restore IL-10 response [89]. This is important
since glucorticoid resistance is a pivotal barrier to the anti
inflammatory treatment of COPD.
Patients with COPD have an increased prevalence of
osteoporosis (from 9-69%) and osteopenia (from 27-
67%) [90-93]. Malnutririon and low vitamin D levels
could be a cause of this higher prevalence [91,94]. The
majority of COPD patients have vitamin D deficiency
[39,41,95-97] therefore vitamin D supplementation in
patients with COPD has been proposed [40].
Black et al reported that higher vitamin D levels were
associated with better lung function [72]. In this study that
used cross-sectional data from the Third National Health
and Nutrition Examination Survey 14.091 people aged >20
years were included. The mean difference between the
highest and the lowest quintile of 25-hydroxyvitamin D
serum concentration was 126 ml in FEV 1, and 172 ml for
FVC after adjustment for factors that affect lung function
(age, gender, smoking, etc) [72] (Table 1).
Vitamin D insufficiency has been reported to be asso-
ciated with an increased incidence of chronic respiratory
infections [29,33-35]. There are some studies that also
suggest that low serum 25-hydroxy vitamin D levels are
associated with upper and lower respiratory tract infec-
tion [33-35]. In one large cross sectional study with
18.883 participants, this association was stronger in
COPD patients [33] (Table 1). Ebstein Barr virus infec-
tion, which is often found in COPD patients, is also
associated with low levels of vitamin D [98,99]. Liou
et al reported a relation between Toll-like receptors,
external triggers and vitamin D-mediated innate immu-
nity, and suggested that differences in the ability of
human populations to produce vitamin D may contri-
bute to susceptibility to microbial infections [100].
Finally, Vitamin D could play an important role as an
antioxidant therapy, not only for the significant
improvement in spirometric values, but also because it
has been proposed as a novel treatment to cachexia and
sarcopenia in COPD patients [101].
Vitamin C and E
The role of vitamin C (also known as ascorbate or
L-ascorbic acid) in the human body is essential. It has
antioxidant properties, is involved in various meta-
bolic reactions, and some studies report it also plays a
role in the immune system [102,103]. It is considered
important for the maintenance of the connective tis-
sue and bone remodeling [102]. Vitamin E has antiox-
idant properties as well, and has been reported to
have a protective role in the prevention of athero-
sclerosis and carcinogenesis [104].
In one study that included 3 European Countries a trend
(P < 0.05) of lower COPD mortality was observed with
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after adjustment for age, smoking and country [16].
Higher levels of vitamin C and E in both serum and FFQ
in healthy subjects were associated with an increase in
FEV1 and FVC [31,32,58-66,69,70]. More details are
depicted in Table 2. In one study an increase of 20 micro-
mol/Lt in plasma vitamin C concentration was associated
with a 13% reduction in the risk of developing obstructive
airway disease OR: 0.87 (CI:0.77-0.98) [75].
Studies regarding the role of vitamin C and E in respira-
tory symptoms showed that low levels were associated
with more wheezing, phlegm production and dyspnea
[28,31,32,36,37]. Tug et al found both vitamin E and vita-
min A levels were significantly lower during exacerbations
of COPD than in patients with stable COPD [30].
Takkouche et al, in 1667 cases of the common cold in
the general population suggested that intake of vitamin C
and zinc was not related to the occurrence of common
cold [105]. Nevertheless vitamin C decreases the duration
of common cold symptoms which might be important in
patients with COPD [106].
Vitamin A and B
Vitamin A (retinol and carotens) plays an important role
in several functions of the human body including vision,
bone and skin health, and further has an innate antioxi-
dant activity. Vitamin B is involved in various steps of
metabolism and enhances immunity. High levels of
vitamin A, b-carotene and/or alpha-carotene were asso-
ciated with increase in FEV1 and FVC in most of the
studies [31,32,63,65,66,69-71,76] although there are
some exceptions [57,61,68]. More details are presented
in Table 2. High serum beta carotene levels in a general
population sample of 523 subjects were associated with
the expression of a gene polymorphism that connected
with a slower FEV1 decline [107].
Hirayama et al reported that the highest level of intake
of vitamin A resulted in a 52% (p = 0.008) reduction in
COPD risk [108] while in another study the risk for
COPD was associated with lower levels of plasma
vitamin A (p < 0.01)[108].
Fimognari et al reported lower levels of folate and
vitamin B12 in COPD patients, resulted in an increased
Table 1 Studies connecting spirometric values or incidence of respiratory infections with Vitamin D
Vitamin
D-Ref
No of
participants
FFQ or plasma
levels
Results
[33] 18.883 Plasma levels Lower 25(OH)D levels were independently associated with recent URTI (odds ratio [OR], 1.36-1,24). The
association between 25(OH)D level and URTI was stronger in patients with chronic obstructive
pulmonary disease odds ratio; 2.26.
[35] 800 Plasma levels Subjects with serum 25(OH)D concentrations < 40 nmol/L (n = 24) had significantly (P = 0.004) more
days of absence from duty due to respiratory infection (median: 4; quartile 1-quartile 3: 2-6) than did
control subjects (2; 0-4; n = 628; incidence rate ratio 1.63; 95% CI: 1.15, 2.24).
[72] 14.091 Plasma levels The mean difference between the highest and the lowest quintile of 25-hydrocyvitamin D serum
concentration was 126 mL (SE:22 mL) in FEV 1, and 172 mL (SE:22 mL) for FVC.
Table 2 Studies connecting Vitamin C, E, A, alpha and beta-carotene with spirometric values improvement
Vitamin FFQ
studies
Plasma
levels
studies
Improvement in spirometric values No
association
with
spirometric
values
Vit C
31,58,59,60,61,
62,63,65,66
32,52, 63,69,70 Serum:FEV1 improvement in ml from 17-94 ml and FVC improvement from 16.4-94 ml for
an SD variation
FFQ: FEV1 improvement in ml from 37-53 ml and FVC improvement from 23.3-79 ml for
an SD variation
52
Vit E
31,58,59,61,
62,64,65
32,69,70 Serum: An SD increase in plasma levels of vitamin E had a median range of FEV1 increase
in ml from 12-59.3 ml
FFQ: An SD increase had a median range of FEV1 increase in ml from 20.1-93 ml and for
FVC from 23.1 -54 ml, respectivelly
31,58,61
Vit A
61,68 32,70 32,70
Serum:Improvement in FEV1 ranges from 22-31.2 ml
61,68
b-
carotene
31,57,
63,65,66,69
32,69, 70, 76 Serum: Improvement in FEV1 ranges from 11-107 ml, FVC 147 ml
FFQ: Improvement in FEV1 = 60 ml, FVC= 75 ml
57
a-
carotene
70,71 70,71
Serum:
Improvement in FEV1 for one SD increase 23.7 ml
70.
Subjects in the fifth quintile of serum beta-carotene had a 195 ml (95% confidence interval
[95% CI]: 40 to 351 ml) higher and those in the fifth quintile of alpha-carotene had a 257
ml (95% CI: 99 to 414 ml) higher FEV(1) compared with subjects in the first quintile of
these carotenoids
71.
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cular risk factor [109].
Regarding the role of b-carotene in respiratory symp-
toms, two studies showed a beneficial association with
cough [32,36] and one study showed no correlation with
symptoms, except for wheezing [31].
Vitamin supplementation
Antioxidant supplementation has been proposed to be
helpful in patients with COPD as a way to reduce oxida-
tive stress and inflammation, and improve spirometric
values [24]. Multivitamin supplementation has been
reported to be popular for patients with COPD espe-
cially among older patients [110].
Seven studies reported the effect of vitamin supple-
ments on several outcomes of COPD [18,36,111-115].
All these studies showed a large heterogeneity regarding:
which vitamins had been supplemented, the dosage and
the duration of the vitamin supplementation, ranging
from 4 weeks to 5 years [111-115]. Secondly, different
outcomes were measured such as spirometric values,
symptoms and exercise capacity. A randomized con-
trolled trial in high-risk individuals for cardiovascular
events that received antioxidant vitamins (vitamin C, E
and b-carotene) supplementation for 5 years failed to
identify any improvement in 5-year mortality and in
spirometric values or hospitalization due to COPD.
However this study excluded patients with severe COPD
[115]. More details are depicted in Table 3. Also a
cohort study of 77,719 participants using multi-vitamin
supplements was not related to the total mortality [116].
Little is known regarding the prevention of upper
respiratory tract infections after supplementation of
Vitamin D although some studies report a trend for
improvement [117] but some others do not confirm that
(ranges of OR = 0.77-0.95) [118,119].
Table 3 Vitamin supplementation and COPD outcome measured
Reference Suplementation No of patients Effect
[18] Supplementation E and C. 10 of 21 COPD
patients were given vitamin E (200 UI/day) and
vitamin C (500 mg/day) for 1 month.
21 COPD and 10 controls. The exercise time increased significantly in the 10
COPD patients who were treated (exercise time
6.4+1.8 vs 8.7+2.1 min, p = 0.01). (Bruce protocol-
graded treadmill exercise test).
[36] Supplementation alpha-tocopherol (50 mg/d)
and beta-carotene (20 mg/d) supplementation,
for 5-8 years.
29.133 people (Cancer
prevention study)
The supplementation did not affected the
reccurence or incidence of chronic cough,
phlegm or dyspnea. Relative risk for the above
mentioned symptoms arround 1 with or without
supplementation.
[111] Vit E supplementation. 400 IU daily for 12 weeks. 30 COPD patients Spirometric measurements. Changed not
significant either on day 1 or after 12 weeks of
vitamin E supplementation.
[112] Vit E supplementation Patients were divided into
two groups: group A- placebo group (n = 14),
receiving only standard therapy, and group B-
vitamin E-supplemented group (n = 10),
receiving 400 IU of vitamin E capsules twice daily
in addition to standard therapy, for 8 weeks.
24 COPD patients. There was a similar degree of lung function and
clinical improvement in both groups.
[113] Vit C and E. Patients were randomly assigned to
placebo (n = 8), 400 mg/day vitamin E (E400, n =
9), 200 mg/day vitamin E (E200, n = 9), or 250
mg/day vitamin C (C250, n = 9) for 12 weeks.
35 COPD patients No improvement in lung function after 12 weeks
of supplementation.
[114] Vit A supplementation for 30 days. (healthy
nonsmokers (n = 7), healthy smokers (n = 7),
mild chronic obstructive pulmonary disease
(COPD-mild) patients (n = 9), COPD-moderate-
severe patients (n = 7), and COPD-moderate-
severe patients with exacerbation (+ex;n = 6)
36 people-21 COPD n = 6). Improvement in lung function mean increase for
1-s forced expiratory volume (FEV1) = 22.9% in
the COPD-vitamin A group.
[115] Supplementation 600 mg vitamin E, 250 mg
vitamin C, and 20 mg b-carotene daily 5-year
treatment period. All participants randomly
allocated to receive vitamin supplementation or
placebo.
20 536 UK adults (aged 40-80)
with coronary disease, other
occlusive arterial disease, or
diabetes
No significant differences were observed between
the treatment groups in forced expiratory volume
during one second (FEV1: 2·06 L vitamin-allocated
vs 2·06 L placebo-allocated; difference 0·00 L [SE
0·01]) or in forced vital capacity (FVC: 2·83 L vs
2·82 L; difference 0·01 L [SE 0·01]). Nor were
significant differences observed in the numbers of
participants hospitalised for chronic obstructive
pulmonary disease or asthma (149 [1·5%] vs 133
[1·3%]) or for any other non-neoplastic respiratory
cause (641 [6·2%] vs 642 [6·3%]).
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The results of this review show that intake of various
vitamins are associated with improvement in features of
COPD such as symptoms, exacerbations and pulmonary
function. Increased vitamin intake could probably reduce
the annual decline of FEV1. Although the mechanisms
behind these effects are often not clear, this might open
possibilities to develop drugs that modify or prevent
COPD. Dietary interventions directed towards high vita-
min intake might be an additional approach towards
COPD management. Although there are many studies
that associate vitamins with improvement in lung function
tests, there is no clear evidence of the benefit of vitamin
supplements. Most studies regarding supplements showed
no benefit of multivitamin supplemention in symptoms,
spirometric function or hospitalization for COPD.
This review suggests that future work is needed with
prospective randomized controlled trials, that would
explore the role of vitamins as well as the effectiveness
of vitamin supplements on outcomes such as symptoms
spirometric values, health status, risk of development of
COPD and exacerbations rates.
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